Lupin Launches Bioequivalent of Xigduo XR in US Across Multiple Strengths
Written By : MD Bureau
Published On 2026-04-23 06:15 GMT | Update On 2026-04-23 06:15 GMT
Advertisement
Mumbai: Pharma major Lupin Ltd on Wednesday announced the launch of its generic version of anti-diabetic medicine dapagliflozin and metformin hydrochloride extended-release tablets in the US following approval by the country's health regulator.
The launched Dapagliflozin and metformin hydrochloride extended-release tablets in the US are of strengths 5 mg/500 mg, 5 mg/1,000 mg, 10 mg/500 mg, 10 mg/1,000 mg, Lupin said in a regulatory filing.
The launch follows the approval for the company's abbreviated new drug application from the USFDA as bioequivalent to Xigduo XR, the company said.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.